ARGX vs. BNTX, NBIX, TECH, QGEN, RGEN, BIIB, PCVX, EXEL, RVMD, and IBRX Should you be buying argenx stock or one of its competitors? The main competitors of argenx include BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Biogen (BIIB), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
argenx (NASDAQ:ARGX ) and BioNTech (NASDAQ:BNTX ) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
In the previous week, argenx had 1 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for argenx and 11 mentions for BioNTech. BioNTech's average media sentiment score of 1.06 beat argenx's score of 0.54 indicating that BioNTech is being referred to more favorably in the news media.
argenx currently has a consensus target price of $524.68, suggesting a potential upside of 43.43%. BioNTech has a consensus target price of $111.70, suggesting a potential upside of 23.28%. Given argenx's stronger consensus rating and higher probable upside, equities analysts clearly believe argenx is more favorable than BioNTech.
argenx received 486 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.86% of users gave argenx an outperform vote while only 42.38% of users gave BioNTech an outperform vote.
BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
60.3% of argenx shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.4% of argenx shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
argenx has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
BioNTech has a net margin of 4.01% compared to argenx's net margin of -22.58%. BioNTech's return on equity of 0.55% beat argenx's return on equity.
Summary argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
